Letter by Donzelli et al Regarding Article, "Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)"

Affiliations

¹ Unit of Appropriateness in Primary Care, Health Protection Agency, Milan, Italy (A.D.).
² Public Health and Preventive Medicine, University of Milano-Bicocca, Milan, Italy (A.S., G.G.).

Comment

Alberto Donzelli et al. Circulation. 2018.

. 2018 Oct 23;138(17):1912-1913.

doi: 10.1161/CIRCULATIONAHA.118.034068.

¹ Unit of Appropriateness in Primary Care, Health Protection Agency, Milan, Italy (A.D.).
² Public Health and Preventive Medicine, University of Milano-Bicocca, Milan, Italy (A.S., G.G.).

No abstract available

Comment on

Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).
Giugliano RP, Cannon CP, Blazing MA, Nicolau JC, Corbalán R, Špinar J, Park JG, White JA, Bohula EA, Braunwald E; IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) Investigators. Giugliano RP, et al. Circulation. 2018 Apr 10;137(15):1571-1582. doi: 10.1161/CIRCULATIONAHA.117.030950. Epub 2017 Dec 20. Circulation. 2018. PMID: 29263150 Clinical Trial.